Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial

OBJECTIVES: The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this modification could potentially retain efficacy benef...

Descripción completa

Detalles Bibliográficos
Autores principales: George, Daniel J, Spigel, David R, Gordan, Lucio N, Kochuparambil, Samith T, Molina, Ana M, Yorio, Jeff, Rezazadeh Kalebasty, Arash, McKean, Heidi, Tchekmedyian, Nishan, Tykodi, Scott S, Zhang, Joshua, Askelson, Margarita, Johansen, Jennifer L, Hutson, Thomas E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476127/
https://www.ncbi.nlm.nih.gov/pubmed/36104138
http://dx.doi.org/10.1136/bmjopen-2021-058396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476127/
https://www.ncbi.nlm.nih.gov/pubmed/36104138
http://dx.doi.org/10.1136/bmjopen-2021-058396

Ejemplares similares